News Pfizer's weekly haemophilia drug backed for NHS use Some patients in England living with severe haemophilia B will soon be able to do away with need for regular infusions.
News Germany will reimburse haemophilia gene therapy Hemgenix Germany has agreed to reimburse CSL Behring's haemophilia B gene therapy Hemgenix with a 'unique' outcomes-based payment model.
News UK haemophilia A patients get once-weekly treatment option A long-acting Factor VIII replacement therapy for haemophilia A from Sobi and Sanofi has been recommended for use by the NHS.
News Pfizer drops Beqvez, leaving its gene therapy cupboard bare Pfizer has abandoned its haemophilia B treatment Beqvez in all world markets, saying weak demand made the business non-viable.
News Pfizer ducks out of Sangamo haemophilia A alliance Sangamo is "surprised and disappointed" by Pfizer's decision to return rights to its gene therapy for haemophilia A after positive phase 3 results.
News Pfizer bags EU okay for haemophilia drug Hympavzi Pfizer's Hympavzi has become the first once-weekly subcutaneous treatment for people living with severe haemophilia B in the EU
R&D Precision, speed, impact: Evolving mass spectrometry for med... MOBILion's Melissa Sherman explores the evolving role of mass spectrometry in drug discovery, complex molecule analysis, and medical research.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face